Federal Patent Court Ruling
Liquidia Shares Plunge 57 Percent Following Federal Court Patent Ruling on Yutrepia
Anonymous
Key Points
1
Yutrepia is a dry-powder inhaled treprostinil product developed with Liquidia’s proprietary PRINT technology, which is designed to deliver the drug deep into the lungs and allow higher doses than other inhaled treprostinil therapies. The FDA approved it in May 2025 for PAH and PH-ILD, and Liquidia launched it in June 2025.
2
The patent dispute began in 2023 after Liquidia sought to add PH-ILD as a Yutrepia indication and notified United Therapeutics it was challenging patents covering inhaled treprostinil. United sued in September 2023 and added the subsequently issued ’327 patent to its case that November.
3
United Therapeutics says it believes it is entitled to an order directing the FDA to withdraw Yutrepia’s New Drug Application approval; if granted, the drug could leave the U.S. market until the FDA approves labeling that excludes PH-ILD.
4
Liquidia had conceded that Yutrepia infringed the two patent claims, so the court’s decision that those claims were valid settled liability. The ruling also came as nebulized Tyvaso sales fell 18% year over year in the second quarter, suggesting Yutrepia had already been winning patients from United Therapeutics.
A Delaware federal court ruled that two patents held by United Therapeutics are valid and infringed by Liquidia's Yutrepia drug, sending Liquidia shares down 57% Yahoo Finance. Yutrepia is Liquidia's main product, recently approved by the FDA in May 2025 for treating two types of pulmonary hypertension. The court's decision creates major uncertainty about whether the drug can remain on the market or must drop its pulmonary hypertension-interstitial lung disease (PH-ILD) indication.
The ruling resolved the validity question but left open what happens next AOL. United Therapeutics is asking the FDA to withdraw Yutrepia's approval entirely. If granted, the drug would be pulled from shelves until the company removes the PH-ILD indication from its label. Liquidia says it plans to appeal the court decision.
How Yutrepia Works and Why It Matters
Yutrepia is a dry-powder inhaled version of treprostinil, a drug that widens blood vessels in the lungs Yahoo Finance. Liquidia uses proprietary PRINT technology to deliver the medicine deep into lung tissue, allowing higher doses than competing inhaled treprostinil products. The FDA approved it in May 2025 for two conditions: pulmonary arterial hypertension (PAH) and PH-ILD. Liquidia launched the drug in June 2025.
Yutrepia represents the company's future. Its commercial success drives Liquidia's entire strategy. Early sales already show the drug grabbing market share from United Therapeutics' own treprostinil product, Tyvaso, which saw nebulized sales drop 18% year over year in the second quarter TradingView. This market shift made the patent dispute existential for both firms.
The Patent Dispute That Started in 2023
The battle began when Liquidia notified United Therapeutics in 2023 that it was challenging patents covering inhaled treprostinil Benzinga. Liquidia wanted to add the PH-ILD indication to Yutrepia. United Therapeutics sued in September 2023 and later added the '327 patent to its case that November. The two companies squared off in Delaware federal court.
Liquidia conceded early on that Yutrepia infringed the two patent claims Yahoo Finance. So the court's decision that those claims were valid settled the infringement question. The court also rejected four other claims United Therapeutics asserted, limiting the patent holder's win. Now the focus shifts to remedies and what restrictions the judge will impose.
Remedies Could Force Yutrepia Off Market or Limit Sales
United Therapeutics is asking for an order to withdraw Yutrepia's New Drug Application from the FDA AOL. If the court grants this, the drug leaves U.S. shelves until the FDA approves new labeling that excludes PH-ILD. This scenario would be catastrophic for Liquidia. The company could still sell Yutrepia for PAH, but losing the PH-ILD indication slashes its market opportunity.
Both companies will now propose their own remedy suggestions to the court TradingView. Liquidia plans to appeal the ruling. Analysts have already cut price targets and downgraded the stock as they reassess Yutrepia's future prospects. The stock's 57% plunge reflects how much the market depends on this one drug to drive Liquidia's growth and survival.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
94
Reach
115
A
AnonymousAuthor
